Cudetaxestat (BLD-0409), an investigational treatment for idiopathic pulmonary fibrosis (IPF) being developed by Blade Therapeutics, does not interact…
Articles by Marisa Wexler, MS
A trio of global companies is teaming up to develop an inhaled dry powder formulation of SF2523, an investigational…
A protein called PDIA3 is overactive in pulmonary fibrosis (PF), and contributes to the disease by driving the production…
The U.S. Food and Drug Administration (FDA) has authorized Blade Therapeutics to begin a Phase 1 clinical…
MyMD Pharmaceuticals has secured a 13th U.S. patent protecting its experimental therapy MYMD-1, which is being investigated as a…
Treatment with two approved antifibrotics did not lessen a risk of death in recently hospitalized idiopathic pulmonary fibrosis (IPF) patients,…
For more than 40% of people with pulmonary fibrosis (PF), obtaining an accurate diagnosis takes a year or longer,…
Measuring the levels of certain molecules in the blood could be useful for distinguishing idiopathic pulmonary fibrosis (IPF) from other…
Switching antifibrotic treatment is generally well-tolerated among people with idiopathic pulmonary fibrosis (IPF), and those who did generally lived…
The Washington Research Foundation (WRF) has awarded a $250,000 grant to support the development of…